Effect of berberine on hyperandrogenemia, ovulation dysfunction and inflammation in a mouse model of polycystic ovary syndrome

被引:2
|
作者
Lu, Kena [1 ]
Lin, Hanmei [1 ]
机构
[1] Guangxi Univ Chinese Med, Affiliated Hosp 1, Dept Gynecol, Nanning, Peoples R China
关键词
Berberine; Polycystic ovary syndrome; Hyperandrogenemia; Ovulation dysfunction; Inflammatory; INSULIN-RESISTANCE;
D O I
10.4314/tjpr.v19i9.23
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Purpose: To study the effect of berberine (BBR) on hyperandrogenemia (HA), ovulation dysfunction and inflammation in a mouse model of polycystic ovary syndrome (PCOS). Methods: Forty-five female Kunming mice were randomly divided into control group (9 mice), and mice injected with dehydroepiandrosterone (n = 36) for establishment of PCOS model. The PCOS mice were randomly divided into model group, low-dose BBR (0.25 g/kg), medium-dose BBR (0.5 g/kg) and highdose (1.0 g/kg) groups, with 9 mice in each group. Changes in ovarian morphology were monitored, and sex hormone levels i.e. testosterone (T) and luteinizing hormone (LH)), and inflammatory factors were determined. Results: The model group levels of T and LH were significantly higher than those of the blank control group (p < 0.05), but T and LH levels were significantly lower in middle- and high-dose BBR groups than in the model mice. There were marked increases in IL-6 and TNF-a levels in model mice, when compared to blank control mice, but reduced in the mice treated at the 3 doses of BBR, relative to model mice (p < 0.05). In contrast, the number of follicles was higher at each stage of development in mice for each BBR dose than in the model mice, with increase in corpus luteum. Conclusion: Berberine lowers the weight of PCOS mice, mitigates hyperandrogenemia and inflammatory state, and enhances recovery of ovulation. However, there is need for further studies on its clinic applicability.
引用
下载
收藏
页码:1963 / 1968
页数:6
相关论文
共 50 条
  • [31] Modelling the control of ovulation and polycystic ovary syndrome
    Chávez-Ross A.
    Franks S.
    Mason H.D.
    Hardy K.
    Stark J.
    Journal of Mathematical Biology, 1997, 36 (1) : 95 - 118
  • [32] Ovulation induction in women with polycystic ovary syndrome
    Perales-Puchalt, Alfredo
    Legro, Richard S.
    STEROIDS, 2013, 78 (08) : 767 - 772
  • [33] Letrozole for ovulation induction in polycystic ovary syndrome
    Doblinger J.
    Griesinger G.
    Gynäkologische Endokrinologie, 2017, 15 (3) : 235 - 238
  • [34] Hyperandrogenemia influences the prevalence of the metabolic syndrome abnormalities in adolescents with the polycystic ovary syndrome
    Fruzzetti, Franca
    Perini, Daria
    Lazzarini, Veronica
    Parrini, Donatella
    Genazzani, Andrea R.
    GYNECOLOGICAL ENDOCRINOLOGY, 2009, 25 (05) : 335 - 343
  • [35] Ovulation induction strategies in polycystic ovary syndrome
    Tanbo, Tom
    Mellembakken, Jan
    Bjercke, Sverre
    Ring, Eva
    Abyholm, Thomas
    Fedorcsak, Peter
    ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA, 2019, 98 (02) : 263 - 263
  • [36] Ovulation induction in women with polycystic ovary syndrome
    Palomba, Stefano
    Orio, Francesco
    Zullo, Fulvio
    FERTILITY AND STERILITY, 2006, 86 : S26 - S27
  • [37] Modelling the control of ovulation and polycystic ovary syndrome
    ChavezRoss, A
    Franks, S
    Mason, HD
    Hardy, K
    Stark, J
    JOURNAL OF MATHEMATICAL BIOLOGY, 1997, 36 (01) : 95 - 118
  • [38] Ovulation induction in women with polycystic ovary syndrome
    Shahla Nader
    Nature Clinical Practice Endocrinology & Metabolism, 2007, 3 : 438 - 439
  • [39] Ovulation induction in polycystic ovary syndrome patients
    Tarlatzis, BC
    Bili, HN
    ADVANCES IN GYNECOLOGICAL ENDOCRINOLOGY, 2002, : 79 - 81
  • [40] Marked hyperandrogenemia and acne associated with polycystic ovaries in Greek women with polycystic ovary syndrome
    Skampardonis, N.
    Kouskoukis, A.
    Karpouzis, A.
    Maroulis, G.
    CLINICAL AND EXPERIMENTAL OBSTETRICS & GYNECOLOGY, 2011, 38 (02): : 168 - 171